Invesco
RXRX icon

Invesco’s Recursion Pharmaceuticals RXRX Stock Holding History

Invesco’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.92M Buy
795,698
+104,545
+15% +$348K ﹤0.01% 2428
2026
Q1 		$2.12M Buy
691,153
+165,009
+31% +$638K ﹤0.01% 2520
2025
Q4 		$2.15M Buy
526,144
+107,979
+26% +$535K ﹤0.01% 2583
2025
Q3 		$2.04M Buy
418,165
+99,053
+31% +$520K ﹤0.01% 2605
2025
Q2 		$1.61M Buy
319,112
+116,581
+58% +$573K ﹤0.01% 2652
2025
Q1 		$1.07M Buy
202,531
+23,912
+13% +$174K ﹤0.01% 2806
2024
Q4 		$1.21M Buy
178,619
+63,068
+55% +$424K ﹤0.01% 2836
2024
Q3 		$761K Buy
115,551
+7,284
+7% +$52.2K ﹤0.01% 3032
2024
Q2 		$812K Buy
108,267
+9,703
+10% +$84.6K ﹤0.01% 3041
2024
Q1 		$983K Sell
98,564
-22,322
-18% -$249K ﹤0.01% 2997
2023
Q4 		$1.19M Buy
120,886
+13,796
+13% +$98.4K ﹤0.01% 2814
2023
Q3 		$819K Buy
107,090
+580
+0.5% +$5.79K ﹤0.01% 2967
2023
Q2 		$796K Sell
106,510
-12,705
-11% -$88.9K ﹤0.01% 2997
2023
Q1 		$795K Buy
119,215
+74,595
+167% +$592K ﹤0.01% 3011
2022
Q4 		$344K Sell
44,620
-332
-0.7% -$3.26K ﹤0.01% 3450
2022
Q3 		$478K Buy
44,952
+669
+2% +$6.78K ﹤0.01% 3266
2022
Q2 		$361K Sell
44,283
-350
-0.8% -$2.34K ﹤0.01% 3495
2022
Q1 		$320K Buy
44,633
+1,160
+3% +$12.3K ﹤0.01% 3607
2021
Q4 		$745K Buy
+43,473
New +$818K ﹤0.01% 3220
2021
Q3 		– Sell
-5,612
Closed -$205K – 4051
2021
Q2 		$205K Buy
+5,612
New +$166K ﹤0.01% 3781

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Invesco's RXRX Position: Q2 2026 in Review

Invesco increased its Recursion Pharmaceuticals (RXRX) stake by 15% in Q2 2026, buying an estimated $348K and bringing the position to 795,698 shares worth $2.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

Invesco first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Invesco held 795,698 shares of Recursion Pharmaceuticals worth $2.92M as of Q2 2026.
  • Invesco bought 104,545 Recursion Pharmaceuticals shares in Q2 2026, an estimated $348K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2428 holding.
  • Invesco first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.